全球液体切片市场（第七版）

液体切片检查透过提供一种微创方法来分析循环于生物体液中的肿瘤衍生物质，彻底改变了癌症诊断方式。这种方法为癌症检测、治疗选择和疾病监测提供了重要的见解，可以补充或取代传统的组织活检和影像技术，而这些技术通常存在操作风险和局限性。

Kalorama Information 的 "全球液体活检市场报告（第七版）" 涵盖了推动其应用的所有临床应用，包括早期检测和筛检、组织活检困难时的替代检测、个人化治疗和抗药性监测、疾病进展和復发监测以及预后评估。

全面的市场分析

"全球液体活检市场报告（第七版）" 提供了 2025 年至 2030 年全球液体活检收入的详细预测，并依以下细分市场进行划分：

• 依地区划分： 北美、欧洲、亚洲和世界其他地区（包括区域市场占有率和成长趋势）
• 技术类型：基于循环肿瘤DNA (ctDNA)、循环肿瘤细胞 (CTC)、细胞外囊泡和外泌体、多分析物以及其他分析物驱动的方法。对比表格列出了每种方法的优点和限制。
• 依癌症类型划分： 乳癌、肺癌、大肠癌、卵巢癌、摄护腺癌、泛癌及其他癌症。针对每种适应症提供收入预测和市场占有率分析。
• 应用领域： 诊断/筛检、治疗指导、微小残留病灶 (MRD) 检测和疾病预后。提供市场规模和成长预测以支援分析。

产业洞察与竞争格局

本报告概述了目前已上市和正在研发的部分液体活检检测技术，包括基于ctDNA的检测、基于CTC的平台以及多分析物解决方案。报告比较了这些技术在临床和研究领域的应用，并分析了监管趋势。报告的详细章节提供了技术比较、特定分析物的市场动态以及应用层面的机遇，并包含十几个表格和图表，展示了收入预测、市场占有率和驱动因素。

范围与方法

本报告涵盖了全球液体活检检测市场。市场数据以检测公司为单位呈现，涵盖全球和区域收入。这与大多数KI报告不同，后者通常提供体外诊断（IVD）产品层面的估算。虽然系统和试剂盒并未被排除在外，但它们并非本报告的主要关注点。大多数公司以服务的形式提供这些检测。

资料基准年为2025年，预测期至2030年。各细分市场的复合年增长率（CAGR）也已提供。

全球液体切片市场的资讯和数据来自广泛的一手和二手资料。我们访问了体外诊断医疗器材（IVD）产品製造商、临床实验室技术人员和其他产业专家。二手资料包括政府机构、产业协会和独立出版商的统计和资讯报告及文章。我们也查阅了主要公司的年度报告、公开文件和网站，以识别不断变化的产品和市场趋势，评估竞争因素，并加强对整个行业的分析。此外，我们也参考了Kalorama Information和Strategic Directions International (SDi)的部分出版物，以获取更多背景资讯。 SDi是Kalorama Information的姊妹出版品牌，隶属于科学与医学集团。

目录

第一章：摘要整理

第二章：液体切片技术

• 引言
• 主要液体切片技术

第三章：循环肿瘤DNA (ctDNA) 液体切片

• 引言
• ctDNA在液体活检中的优势和局限性
• 基于ctDNA的液体切片检测
  • Adaptive Biotechnologies
  • Biocartis
  • Biodesix
  • CellMax Life
  • Circulogene
  • DiaCarta
  • Foundation Medicine (Roche)
  • Guardant Health
  • LungLife AI
  • Myriad Genetics
  • Natera
  • NeoGenomics
  • OncoDNA
  • Personal Genome Diagnostics (Labcorp)
  • QIAGEN
  • Resolution Biosciences (Exact Sciences)
  • Roche Diagnostics
  • Sysmex-Inostics
  • Tempus
• 基于循环肿瘤细胞 (ctDNA) 的液体活检检测的开发
  • BillionToOne
  • Cyclomics
  • Exact Sciences
  • Freenome
  • GRAIL

第四章：循环肿瘤细胞 (CTC) 液体切片

• 引言
• 基于 CTC 的液体活检检测开发中的挑战
• 基于 CTC 的液体活检检测
  • Adaptive Biotechnologies
  • ANGLE
  • CellMax Life
  • Epic Sc​​ienceces
  • GILUPI
  • LungLife AI
  • Menarini-Silicon Biosystems
  • QIAGEN
• 基于循环肿瘤细胞 (CTC) 的液体切片检测（研发中）
  • BioFluidica
  • Epic Sc​​ienceces
  • QCDx

第五章：细胞外囊泡和其他液体切片

• 引言
• 基于细胞外囊泡/其他分析物的液体活检检测
  • Biodesix
  • Exosome Diagnostics
  • Mercy BioAnalytics
• 细胞外囊泡液体切片检测的研发
• 基于囊泡/其他分析物的液体活检检测
  • EValuate Diagnostics
  • Insight Molecular Diagnostics（原 OncoCyte）
  • Nanostics
  • VolitionRx

第六章：多分析物液体切片检测

• 引言
• 多分析物液体切片检测
  • Biodesix
  • Foundation Medicine（罗氏）
  • LungLife AI
  • NeoGenomics
  • OncoDNA
• 多分析物液体切片检测的开发
  • Exact Sciences
  • Freenome
  • GRAIL
  • LungLife人工智慧

第七章：研究性液体切片

• 引言
• 研究性液体切片
  • Agena Bioscience
  • DiaCarta
  • Exosome Diagnostics
  • Guardant Health
  • QIAGEN

第八章：液体切片产业分析

• 引言
• 竞争格局
• 竞争因素
• 主要市场趋势
• 个人化医疗
• 液体切片市场竞争对手的消失

第九章：液体切片市场

• 市场概览
• 市场预测

第十章：依分析物划分的市场

• 整体市场
• 循环肿瘤DNA
• 细胞外囊泡及其他分析物
• 多种分析物

第十一章：依应用划分的市场

• 概述
• 治疗指导与监测
• 诊断/筛检
• 疾病预后

第十二章：依癌症类型划分的市场

• 整体市场
• 所有癌症筛检
• 肺癌
• 摄护腺癌
• 大肠直肠癌
• 乳癌
• 卵巢癌
• 其他癌症

第十三章：公司资料

• 适应性生物技术
• Agena Bioscience, Inc.
• 安格有限公司
• Aspira 女性健康
• Biocartis 集团 NV
• Biodesix
• CellMax Life
• 环基因
• 迪亚卡塔公司
• 史诗科学
• 精确科学
• Freenome, Inc.
• 吉鲁皮有限公司
• 圣杯
• Guardant Health, Inc.
• 豪洛捷
• LungLife AI（原 Cynvenio Biosystems）
• MDx健康
• Menarini-Silicon Biosystems，水疗中心
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• OncoDNA S.A.
• 个人基因组诊断
• QIAGEN N.V.
  • 无细胞DNA技术
  • CTC Technologies
  • 外泌体和miRNA技术
• Resolution Biosciences（Exact Sciences）
• Roche Diagnostics
• Sysmex-Inostics, Inc.
• Tempus AI

Liquid biopsies have transformed cancer diagnostics by offering a minimally invasive method to analyze tumor-derived materials circulating in biological fluids. This approach provides critical insights for cancer detection, therapy selection, and disease monitoring, complementing or replacing traditional tissue biopsies and imaging techniques that often carry procedural risks and limitations.

Kalorama Information's "The Worldwide Market for Liquid Biopsy, 7th Edition" explores the full spectrum of clinical applications driving adoption, including early detection and screening, alternative testing when tissue biopsy is impractical, therapy personalization and monitoring for resistance, disease surveillance for progression and recurrence, and prognostic assessment.

Comprehensive Market Analysis

"The Worldwide Market for Liquid Biopsy, 7th Edition" delivers a detailed forecast of global liquid biopsy revenues from 2025 to 2030, segmented by:

• Geographic Region: North America, Europe, Asia, and Rest of World, with regional market shares and growth trends.
• Technology Type: Circulating Tumor DNA (ctDNA)-based, Circulating Tumor Cell (CTC)-based, Extracellular Vesicle and Exosome-based, Multi-Analyte-based, and other analyte-driven approaches, including comparative tables of advantages and limitations.
• Cancer Type: Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, and Other Cancers, with revenue forecasts and share analysis for each indication.
• Application: Diagnosis and Screening, Therapy Guidance, Minimal Residual Disease (MRD), and Disease Prognosis, supported by market sizing and growth projections.

Industry Insights and Competitive Landscape

The report profiles selected liquid biopsy tests currently available and in development, including ctDNA-based assays, CTC-based platforms, and multi-analyte solutions. It examines clinical versus research use and regulatory trends. Detailed chapters cover technology comparisons, analyte-specific market dynamics, and application-level opportunities, supported by over a dozen tables and figures illustrating revenue forecasts, market shares, and growth drivers.

Scope and Methodology

This report covers the global market for liquid biopsy testing. The market data pertains to global and regional revenues at the level of testing companies. This differs from most KI reports, which provide estimates at the level of IVD products. While systems and kits are not excluded, they were not the primary focus of this report. Most companies offer these tests as services.

The base year for data is 2025, with forecasts provided through 2030. Compound annual growth rates (CAGRs) are included for each segment.

Information and data on the global liquid biopsy market were obtained from a wide range of primary and secondary sources. Interviews were conducted with manufacturers of IVD products, clinical laboratory technicians, and other industry experts. Secondary sources included statistical and informational reports and articles from government agencies, trade associations, and independent publishing firms. Annual reports, public filings, and websites of leading companies were also reviewed to identify evolving product and market trends, assess competitive factors, and support the overall industry analysis. Selected Kalorama Information and Strategic Directions International (SDi) publications were also consulted for additional background and context. SDi is Kalorama Information's sister publishing brand with the Science and Medicine Group.

Table of Contents

Chapter 1: Executive Summary

• About Kalorama Information
• Scope and Methodology
• Introduction
• Liquid Biopsy Technologies
• Industry Structure
• Liquid Biopsy Market Revenues and Forecast
  • Figure 1-1: Global Market for Liquid Biopsy, 2025-2030 ($ million)
  • Figure 1-2: Global Liquid Biopsy Market, Share by Geographic Region, 2025 (%)
  • Figure 1-3: Global Liquid Biopsy Market, by Geographic Region, 2025 vs. 2030 ($ million) [Asia Pacific, Europe, North America, Rest of World]

Chapter 2: Liquid Biopsy Technologies

• Introduction
• Major Liquid Biopsy Technologies

Chapter 3: Circulating Tumor DNA (ctDNA) Liquid Biopsy

• Introduction
• Advantages and Limitations of ctDNA in Liquid Biopsy
• ctDNA-based Liquid Biopsy Tests
  • Adaptive Biotechnologies
  • Biocartis
  • Biodesix
  • CellMax Life
  • Circulogene
  • DiaCarta
  • Foundation Medicine (Roche)
  • Guardant Health
  • LungLife AI
  • Myriad Genetics
  • Natera
  • NeoGenomics
  • OncoDNA
  • Personal Genome Diagnostics (Labcorp)
  • QIAGEN
  • Resolution Biosciences (Exact Sciences)
  • Roche Diagnostics
  • Sysmex-Inostics
  • Tempus
• ctDNA-based Liquid Biopsy Tests in Development
  • BillionToOne
  • Cyclomics
  • Exact Sciences
  • Freenome
  • GRAIL

Chapter 4: Circulating Tumor Cells (CTCs) Liquid Biopsy

• Introduction
• Challenges in the Development of CTC-based Liquid Biopsy Tests
• CTC-based Liquid Biopsy Tests
  • Adaptive Biotechnologies
  • ANGLE
  • CellMax Life
  • Epic Sciences
  • GILUPI
  • LungLife AI
  • Menarini-Silicon Biosystems
  • QIAGEN
• Selected CTC-based Liquid Biopsy Tests in Development
  • BioFluidica
  • Epic Sciences
  • QCDx

Chapter 5: Extracellular Vesicles and Other Liquid Biopsy

• Introduction
• Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
  • Biodesix
  • Exosome Diagnostics
  • Mercy BioAnalytics
• Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
  • EValuate Diagnostics
  • Insight Molecular Diagnostics (formerly OncoCyte)
  • Nanostics
  • VolitionRx

Chapter 6: Multi-Analyte Liquid Biopsy Tests

• Introduction
• Liquid Biopsy Tests Based on Multiple Analytes
  • Biodesix
  • Foundation Medicine (Roche)
  • LungLife AI
  • NeoGenomics
  • OncoDNA
• Multiple Analyte-based Liquid Biopsy Tests in Development
  • Exact Sciences
  • Freenome
  • GRAIL
  • LungLife AI

Chapter 7: Liquid Biopsy Tests for Research Use Only

• Introduction
• Liquid Biopsy Tests for Research Use Only
  • Agena Bioscience
  • DiaCarta
  • Exosome Diagnostics
  • Guardant Health
  • QIAGEN

Chapter 8: Liquid Biopsy Industry Analysis

• Introduction
• Tiers of Competition
• Competitive Factors
• Significant Market Trends
• Personalized Medicine
  • Increasing Global Life Expectancy
  • New Liquid Biopsy Products
  • Increasing Accessibility of Genetic Testing
  • Regulatory Hurdles
  • Third-Party Payor Coverage
  • Demonstrated Clinical Utility
  • Incidence Rates of Specific Cancers
• Competitors No Longer in the Liquid Biopsy Market

Chapter 9: Liquid Biopsy Market

• Market Overview
  • Figure 9-1: Global Liquid Biopsy Market, by Geographic Region, 2025 vs. 2030 ($ million) [Asia Pacific, Europe, North America, Rest of World]
  • Regional Market Overview
    • Figure 9-2: Global Liquid Biopsy Market, Share by Geographic Region, 2025 vs. 2030 (%)
  • Clinical vs. Research Use
• Market Forecast

Chapter 10: Market by Analyte

• Overall
  • Analyte Analysis
    • Figure 10-1: Global Liquid Biopsy Market, by Analyte, 2025 vs. 2030 ($ million) [Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Multiple Analytes]
    • Figure 10-2: Global Liquid Biopsy Market, Share by Analyte, 2025 vs. 2030 (%) [Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Multiple Analytes]
• Circulating Tumor DNA
  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast
  • Circulating Tumor Cells
  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast
• Extracellular Vesicles and Other Analytes
  • Market Overview
  • Applications
  • Technologies
  • Specimens
  • Revenue Forecast
• Multiple Analytes
  • Market Overview
  • Revenue Forecast

Chapter 11: Market by Application

• Overview
  • Application Analysis
    • Figure 11-1: Global Liquid Biopsy Market, by Application, 2025 vs. 2030 ($ million) [Diagnosis and Screening, Disease Prognosis, Minimal Residual Disease (MRD), Therapy Guidance]
    • Figure 11-2: Global Liquid Biopsy Market, Share by Application, 2025 vs. 2030 (%) [Diagnosis and Screening, Disease Prognosis, Minimal Residual Disease (MRD), Therapy Guidance]
• Therapy Guidance and Monitoring
  • Market Overview
  • Revenue Forecast
  • Minimal Residual Disease (MRD)
  • Market Overview
  • Revenue Forecast
• Diagnosis/Screening
  • Market Overview
  • Revenue Forecast
• Disease Prognosis
  • Market Overview
  • Revenue Forecast

Chapter 12: Market by Cancer Type

• Overall
  • Cancer Type Analysis
    • Figure 12-1: Global Liquid Biopsy Market, by Cancer Type, 2025 vs. 2030 ($ million) [Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pan-Cancer Testing, Prostate Cancer, Other Cancers]
    • Figure 12-2: Global Liquid Biopsy Market, Share by Cancer Type, 2025 vs. 2030 (%) [Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pan-Cancer Testing, Prostate Cancer, Other Cancers]
• Pan-Cancer Tests
  • Market Overview
  • Revenue Forecast
• Lung Cancer
  • Market Overview
  • Revenue Forecast
• Prostate Cancer
  • Market Overview
  • Revenue Forecast
• Colorectal Cancer
  • Market Overview
  • Revenue Forecast
• Breast Cancer
  • Market Overview
  • Revenue Forecast
• Ovarian Cancer
  • Market Overview
  • Revenue Forecast
• Other Cancers
  • Market Overview
  • Revenue Forecast

Chapter 13: Company Profiles

• Adaptive Biotechnologies
• Agena Bioscience, Inc.
• ANGLE plc
• Aspira Women's Health
• Biocartis Group NV
• Biodesix
• CellMax Life
• Circulogene
• DiaCarta, Inc.
• Epic Sciences
• Exact Sciences
• Freenome, Inc.
• GILUPI GmbH
• GRAIL
• Guardant Health, Inc.
• Hologic
• LungLife AI (formerly Cynvenio Biosystems)
• MDxHealth
• Menarini-Silicon Biosystems, Spa
• Natera, Inc.
• NeoGenomics Laboratories, Inc.
• OncoDNA S.A.
• Personal Genome Diagnostics
• QIAGEN N.V.
  • Cell-free DNA Technologies
  • CTC Technologies
  • Exosome and miRNA Technologies
• Resolution Biosciences (Exact Sciences)
• Roche Diagnostics
• Sysmex-Inostics, Inc.
• Tempus AI